Shrier Wealth Management LLC Acquires Shares of 14,244 Gilead Sciences, Inc. $GILD

Shrier Wealth Management LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 14,244 shares of the biopharmaceutical company’s stock, valued at approximately $1,748,000.

Other institutional investors also recently modified their holdings of the company. Corundum Trust Company INC bought a new position in shares of Gilead Sciences in the 3rd quarter worth $26,000. Howard Hughes Medical Institute bought a new stake in Gilead Sciences during the 2nd quarter valued at $30,000. MTM Investment Management LLC increased its stake in Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares in the last quarter. Kilter Group LLC acquired a new position in Gilead Sciences during the second quarter worth $33,000. Finally, Board of the Pension Protection Fund acquired a new position in Gilead Sciences during the fourth quarter worth $37,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $139.37 on Wednesday. The company has a fifty day moving average price of $144.62 and a 200-day moving average price of $129.06. The firm has a market cap of $172.99 billion, a price-to-earnings ratio of 20.59, a PEG ratio of 1.79 and a beta of 0.37. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.Gilead Sciences’s revenue was up 4.7% on a year-over-year basis. During the same period last year, the business posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were given a dividend of $0.82 per share. The ex-dividend date of this dividend was Friday, March 13th. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is 48.45%.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $144.23, for a total value of $432,690.00. Following the transaction, the insider directly owned 131,779 shares of the company’s stock, valued at approximately $19,006,485.17. The trade was a 2.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $144.23, for a total transaction of $432,690.00. Following the transaction, the chief financial officer owned 179,191 shares of the company’s stock, valued at approximately $25,844,717.93. The trade was a 1.65% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 299,280 shares of company stock valued at $42,820,550. 0.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on GILD. Oppenheimer lifted their price objective on shares of Gilead Sciences from $128.00 to $165.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. Cantor Fitzgerald upped their target price on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. Daiwa Securities Group raised their price target on shares of Gilead Sciences from $129.00 to $161.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Argus lifted their price target on Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Finally, Leerink Partners boosted their price objective on Gilead Sciences from $146.00 to $148.00 and gave the stock an “outperform” rating in a report on Wednesday, February 11th. Twenty-four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $157.62.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.